Genzyme Reports Financial Results for Fourth Quarter of 2009 and Full Year
- Details
- Category: Genzyme
Genzyme Corp. (NASDAQ: GENZ), a diversified, global biotechnology company, today announced fourth-quarter and full year 2009 financial results and provided 2010 guidance that reflects growth across its businesses and a focus on strengthening core areas of the company.
AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement
- Details
- Category: AstraZeneca
AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialisation of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.
Abbott Completes Acquisition of Solvay Pharmaceuticals
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced that it has completed its EUR 4.5 billion ($6.2 billion) acquisition of Belgium-based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key global emerging markets.
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir® (ritonavir) Tablets
- Details
- Category: Abbott
Abbott announced that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir® (ritonavir). The new Norvir tablets can be stored at room temperature and do not require refrigeration, making it more convenient for patients.
Roche study drug may offer valuable new treatment option for patients with type 2 diabetes
- Details
- Category: Roche
Roche has announced that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies.
Lilly's Online, Interactive Health Education Program Receives Two Web Awards
- Details
- Category: Eli Lilly and Company
Lilly USA recently was recognized by the eHealthcare Leadership Awards and the Web Marketing Association for its Health Education Answers program, an interactive health and wellness tool.
Novartis gains exclusive rights to Debio 025
- Details
- Category: Novartis
Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C.
More Pharma News ...
- US FDA Approves New Indication for Crestor (Rosuvastatin Calcium)
- Denosumab Trial met Primary and all Secondary Endpoints
- Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness
- GSK launches new specialist unit to research and develop medicines for rare diseases
- Strong operating performance for Roche in 2009
- Pfizer Reports Fourth-Quarter and Full-Year 2009 Results
- VYVANSE® - new ADHD treatment option - now available in Canada